secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001453687-24-000081
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Q1 2024 net loss $56.8M; cash $104.8M; MG Phase 2b data on track for mid-2024
--------------------------------------------------------------------------------

- Net loss $56.8M ($10.50/shr) vs $21.7M ($4.24/shr) Q1 2023; loss widened on higher G&A from merger.
- Cash, equivalents, restricted cash $104.8M; expected to fund operations into 2H 2026.
- R&D expenses $9.7M (down from $18.6M) on pipeline reprioritization; G&A $9.5M (up from $5.7M) on merger costs.
- Phase 2b topline for Descartes-08 in myasthenia gravis expected mid-2024; SLE Phase 2 dosing starts Q2 2024.
- Completed 1-for-30 reverse stock split and preferred conversion; new Maryland HQ expanding manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/0001453687-24-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/rnac-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer